Vancouver, British Columbia, Canada, September 23, 2025 – TheNewswire - PanGenomic Health Inc. (“PanGenomic Health” or the “Company”) (CSE: NARA, FSE:LL30) is pleased to announce that its wholly-owned subsidiary, Mindleap Health Inc. (“Mindleap Health"), plans to establish its Health AI Centre operations in Hong Kong.

 

“Mindleap Health is developing a real-world evidence (“RWE”) platform for the Complementary & Alternative Medicine (“CAM”) market and key to this platform will be access to health datasets in Asia and AI models developed by researchers in Asia”, said Robert Nygren, Executive Chair of PanGenomic Health and President of its wholly-owned subsidiary Mindleap Health. “With the support of a strategic advisory firm based in Hong Kong, we will set up a Health AI Centre in the fourth quarter of this year that will include development, research and marketing resources to advance our Mindleap RWE platform for CAM.”

 

The Mindleap RWE platform will collect and analyze health data from a broad range of traditional and non-traditional sources, including clinical research studies from Western and non-Western countries, long-documented history of human use and evidence of modern use. The goal of the Mindleap RWE platform will be to become a trusted source of information about non-pharmaceutical health solutions.

 

Mindleap Health selected Hong Kong to be the location of its Health AI Centre given Hong Kong's diverse patient populations, its strong government support for AI-driven healthcare and its status as a hub for medical technology innovation in the Asia Pacific region. Hong Kong also provides access to a range of multi-lingual university researchers focused on data science, artificial intelligence, and interdisciplinary collaboration.  

 

About Mindleap Health

 

Mindleap Health is a provider of holistic health and wellness information. To learn more about Mindleap Health’s products and services: www.mindleap.com or email: support@mindleap.com

 

About PanGenomic Health

 

PanGenomic Health is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments. Registered as a British Columbia benefit company, PanGenomic Health's mission is to promote alternative health solutions tailored to the health profile of each individual. To learn more about PanGenomic Health’s products and services: www.pangenomic.com or email: info@pangenomic.com.

 

For more information, please contact:

 

Fairfax Partners Inc. Daniel Southan-Dwyer, President +1 604 366 6277 connect@fairfaxpartners.ca

 

This news release includes certain statements that may be deemed “forward-looking statements”, including statements respecting the services to be provided by PanGenomic Health and the consideration to be paid to PanGenomic Health. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward looking statements. Although PanGenomic Health believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because PanGenomic Health can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in PanGenomic Health’s disclosure documents which can be found under PanGenomic Health’s profile on www.sedarplus.ca.  These risk factors include the possibility of delays in PanGenomic Health’s development efforts, PanGenomic Health not having sufficient financial resources to complete its development efforts in a timely manner and other risks, including those that may be outside of the control of PanGenomic Health.  Except as required under applicable securities legislation, PanGenomic Health undertakes no obligation to publicly update or revise forward-looking statements.

 

The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.